Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Relay Therapeutics (RLAY)
NASDAQ:RLAY
Relay Therapeutics (RLAY) Stock Price & Analysis
297 Followers
RLAY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.70 - $13.32
Previous Close$6.64
Volume1.51M
Average Volume (3M)1.21M
Market Cap
$881.40M
Enterprise Value$791.13M
Total Cash (Recent Filing)$143.74M
Total Debt (Recent Filing)$53.47M
Price to Earnings (P/E)-2.5
Beta1.86
Next Earnings
Aug 07, 2024EPS Estimate
-$0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.64
Shares Outstanding132,741,677
10 Day Avg. Volume1,232,389
30 Day Avg. Volume1,212,708
Standard Deviation0.19
R-Squared0.20
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.18
Price to Sales (P/S)34.50
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue30.97
Enterprise Value/Gross Profit30.97
Enterprise Value/Ebitda-2.87
Forecast
1Y Price Target
$22.14Price Target Upside233.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Relay Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyInavolisib triplet combo hits primary endpoint in Phase 3 for PIK3CA-mutated, HR+, HER2- breast cancer patients, showing a significant reduction in the risk of disease progression or death.
Financial ValuationRLAY is trading at an attractive valuation with an enterprise value significantly lower than the average, hinting at a possible undervaluation of their promising pipeline.
Regulatory MilestoneRoche plans to submit these compelling Phase 3 results to regulatory authorities, which could lead to a new treatment option for breast cancer patients.
Bears Say
Clinical DevelopmentRLAY is pausing further investment in the cholangiocarcinoma program, potentially limiting the scope of their pipeline.
Drug SafetyConcerning safety, dose reductions or interruptions and Rx discontinuation due to AEs occurred in 82.7% and 6.8% of patients, respectively.
Pipeline ValuationThere is less than $1 priced in for Relay's pipeline with RLAY trading at ~$7 per share, and ~$6 per share in cash.
---
Ownership Overview
Currently, No data available
---
RLAY FAQ
What was Relay Therapeutics’s price range in the past 12 months?
Relay Therapeutics lowest stock price was $5.70 and its highest was $13.32 in the past 12 months.
What is Relay Therapeutics’s market cap?
Currently, no data Available
When is Relay Therapeutics’s upcoming earnings report date?
Relay Therapeutics’s upcoming earnings report date is Aug 07, 2024 which is in 79 days.
How were Relay Therapeutics’s earnings last quarter?
Relay Therapeutics released its earnings results on May 02, 2024. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.727 by $0.107.
Is Relay Therapeutics overvalued?
According to Wall Street analysts Relay Therapeutics’s price is currently Undervalued.
Does Relay Therapeutics pay dividends?
Relay Therapeutics does not currently pay dividends.
What is Relay Therapeutics’s EPS estimate?
Relay Therapeutics’s EPS estimate is -$0.74.
How many shares outstanding does Relay Therapeutics have?
Relay Therapeutics has 132,741,680 shares outstanding.
What happened to Relay Therapeutics’s price movement after its last earnings report?
Relay Therapeutics reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.727. Following the earnings report the stock price went down -0.565%.
Which hedge fund is a major shareholder of Relay Therapeutics?
Among the largest hedge funds holding Relay Therapeutics’s share is Baker Bros Advisors LP. It holds Relay Therapeutics’s shares valued at 13M.
---
Relay Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.14 (233.43% Upside)
$22.14 (233.43% Upside)
Blogger Sentiment
Bullish
RLAY Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $60.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.90%
12-Months-Change
Fundamentals
Return on Equity
-40.40%
Trailing 12-Months
Asset Growth
-18.90%
Trailing 12-Months
Company Description
Relay Therapeutics
Relay Therapeutics Inc is a precision medicines company focused on enhancing small molecule therapeutic discovery in targeted oncology. Its pipeline products include RLY-1971 and RLY-4008 and among others.
---
RLAY Stock 12 Month Forecast
Average Price Target
$22.14
▲(233.43% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Meiragtx Holdings
―
Best Analysts Covering RLAY
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-34.86%
reiterated a buy rating 12 days ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -34.86% per trade.
---